J Cancer 2017; 8(18):3856-3861. doi:10.7150/jca.21267

Review

Roles of microRNAs in the resistance to platinum based chemotherapy in the non-small cell lung cancer

Hongjing Zang1, Jianlun Peng2, Weiyuan Wang1, Songqing Fan1✉

1. Department of Pathology, the Second Xiangya Hospital of Central South University, Changsha, Hunan, 410013, China
2. Department of Pathology, School of Basic Medical Science, Central South University, Changsha, Hunan, 410011, China

Abstract

Platinum-based adjuvant chemotherapy improves survival among patients with lung tumors, in particular non-small cell lung cancer (NSCLC). But the predicament of drug resistance in NSCLC patients is frustrating us. The profiles of microRNAs are different between platinum chemotherapy resistant and sensitive NSCLC cells. Researches regarding microRNAs and their targets, in platinum drug resistant cases, illuminate novel ideals for platinum-based chemotherapy for NSCLC patients. Therefore, in this review we will focus on three aspects: Epithelial-mesenchymal transition (EMT), cell proliferation and apoptosis, and the roles of microRNAs in cisplatin (CDDP) and carboplatin (CBP) resistance.

Keywords: microRNAs, platinum drugs, cisplatin, carboplatin, drug resistance, non-small cell lung cancer

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Zang H, Peng J, Wang W, Fan S. Roles of microRNAs in the resistance to platinum based chemotherapy in the non-small cell lung cancer. J Cancer 2017; 8(18):3856-3861. doi:10.7150/jca.21267. Available from http://www.jcancer.org/v08p3856.htm